A Multiple-Center, Retrospective Study of Characteristics and Outcomes of Hospitalized COVID-19 Patients with Cardiovascular Disease in North Iran

Overview

Journal Ethiop J Health Sci

Specialty Health Services

Date 2023 Mar 9

PMID 36890939

Authors

Abazar Pournajaf

Mehrdad Halaji

Farzin Sadeghi

Mohammad Chehrazi

Mostafa Javanian

Masoumeh Bayani

Mahmoud Sadeghi Haddad Zavareh

Mehran Shokri

Mohsen Mohammadi

Iraj Jafaripour

Roghayeh Pourkia

Mehrdad Saravi

Kamyar Amin

Naghmeh Zieaie Amiri

Mohammad Taghi Hedayati Goudarzi

Farzad Jalali

Yousef Yahyapour

Affiliations

Soon will be listed here.

Abstract

Background: In this retrospective study, we investigated the outcomes and demographic characteristics of COVID-19 patients with and without a history of CVD.

Methods: This large retrospective, multicenter study was performed on inpatients with suspected COVID-19 pneumonia who were admitted across four hospitals in Babol, Northern Iran.Demographic data, clinical data, and cycle threshold value (Ct) results of Real Time PCR were obtained. Then, participants were divided into two groups: (1) cases with CVDs, (2) cases without CVDs.

Results: A total of 11097 suspected COVID-19 cases with a mean ± SD age of 53 ±25.3 (range: 0 to 99) years were involved in the present study. Out of whom 4599 (41.4%) had a positive RT-PCR result. Of those, 1558 (33.9%) had underlying CVD. Patients with CVD had significantly more co-morbidities such as hypertension, kidney disease, and diabetes. Moreover, 187 (12%) and 281 (9.2%) of patients with and without CVD died, respectively. Also, mortality rate was significantly high among the three groups of Ct value in patients with CVD, with the highest mortality in those with Ct between 10 and 20 (Group A = 19.9%).

Conclusions: In summary, our results highlight that CVD is a major risk factor for hospitalization and the severe consequences of COVID-19. Death in CVD group is significantly higher compared to non-CVD. In addition, the results show that age-related diseases can be a serious risk factor for the severe consequences of COVID-19.

References

Iorga A, Cunningham C, Moazeni S, Ruffenach G, Umar S, Eghbali M . The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ. 2017; 8(1):33. PMC: 5655818. DOI: 10.1186/s13293-017-0152-8. View

Kong K, Jung S, Yu M, Park J, Kang I . Association Between Cardiovascular Risk Factors and the Severity of Coronavirus Disease 2019: Nationwide Epidemiological Study in Korea. Front Cardiovasc Med. 2021; 8:732518. PMC: 8458703. DOI: 10.3389/fcvm.2021.732518. View

Chavez-Reyes J, Escarcega-Gonzalez C, Chavira-Suarez E, Leon-Buitimea A, Vazquez-Leon P, Morones-Ramirez J . Susceptibility for Some Infectious Diseases in Patients With Diabetes: The Key Role of Glycemia. Front Public Health. 2021; 9:559595. PMC: 7921169. DOI: 10.3389/fpubh.2021.559595. View

Trunfio M, Venuti F, Alladio F, Longo B, Burdino E, Cerutti F . Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. Viruses. 2021; 13(2). PMC: 7917896. DOI: 10.3390/v13020281. View

Mirzaei R, Karampoor S, Sholeh M, Moradi P, Ranjbar R, Ghasemi F . A contemporary review on pathogenesis and immunity of COVID-19 infection. Mol Biol Rep. 2020; 47(7):5365-5376. PMC: 7323602. DOI: 10.1007/s11033-020-05621-1. View

Morgan A, Zakeri R, Quint J . Defining the relationship between COPD and CVD: what are the implications for clinical practice?. Ther Adv Respir Dis. 2018; 12:1753465817750524. PMC: 5937157. DOI: 10.1177/1753465817750524. View

Jalali F, Hatami F, Saravi M, Jafaripour I, Hedayati M, Amin K . Characteristics and outcomes of hospitalized patients with cardiovascular complications of COVID-19. J Cardiovasc Thorac Res. 2022; 13(4):355-363. PMC: 8749360. DOI: 10.34172/jcvtr.2021.53. View

Mirmoeeni S, Azari Jafari A, Hashemi S, Angouraj Taghavi E, Azani A, Ghasrsaz H . Cardiovascular manifestations in COVID-19 patients: A systematic review and meta-analysis. J Cardiovasc Thorac Res. 2021; 13(3):181-189. PMC: 8493234. DOI: 10.34172/jcvtr.2021.30. View

Matsushita K, Ding N, Kou M, Hu X, Chen M, Gao Y . The Relationship of COVID-19 Severity with Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and Meta-Analysis. Glob Heart. 2020; 15(1):64. PMC: 7546112. DOI: 10.5334/gh.814. View

10.

Hu B, Guo H, Zhou P, Shi Z . Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2020; 19(3):141-154. PMC: 7537588. DOI: 10.1038/s41579-020-00459-7. View

11.

Inciardi R, Adamo M, Lupi L, Cani D, Di Pasquale M, Tomasoni D . Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020; 41(19):1821-1829. PMC: 7239204. DOI: 10.1093/eurheartj/ehaa388. View

12.

Wright J, Achana F, Diwakar L, Semple M, Carroll W, Baillie K . Cycle threshold values are inversely associated with poorer outcomes in hospitalized patients with COVID-19: a prospective, observational cohort study conducted at a UK tertiary hospital. Int J Infect Dis. 2021; 111:333-335. PMC: 8364147. DOI: 10.1016/j.ijid.2021.08.022. View

13.

Halaji M, Heiat M, Faraji N, Ranjbar R . Epidemiology of COVID-19: An updated review. J Res Med Sci. 2021; 26:82. PMC: 8548902. DOI: 10.4103/jrms.JRMS_506_20. View

14.

Waudby-West R, Parcell B, Palmer C, Bell S, Chalmers J, Siddiqui M . The association between SARS-CoV-2 RT-PCR cycle threshold and mortality in a community cohort. Eur Respir J. 2021; 58(1). PMC: 8246006. DOI: 10.1183/13993003.00360-2021. View

15.

Mirjalili H, Dastgheib S, Shaker S, Bahrami R, Mazaheri M, Sadr-Bafghi S . Proportion and mortality of Iranian diabetes mellitus, chronic kidney disease, hypertension and cardiovascular disease patients with COVID-19: a meta-analysis. J Diabetes Metab Disord. 2021; 20(1):905-917. PMC: 7907796. DOI: 10.1007/s40200-021-00768-5. View

16.

Aghamollaei H, Sarvestani R, Bakherad H, Zare H, Guest P, Ranjbar R . Emerging Technologies for the Treatment of COVID-19. Adv Exp Med Biol. 2021; 1321:81-96. DOI: 10.1007/978-3-030-59261-5_7. View

17.

Zacharioudakis I, Prasad P, Zervou F, Basu A, Inglima K, Weisenberg S . Association of SARS-CoV-2 Genomic Load with Outcomes in Patients with COVID-19. Ann Am Thorac Soc. 2020; 18(5):900-903. PMC: 8086542. DOI: 10.1513/AnnalsATS.202008-931RL. View

18.

Shah V, Farah W, Hill J, Hassett L, Binnicker M, Yao J . Association Between SARS-CoV-2 Cycle Threshold Values and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. Open Forum Infect Dis. 2021; 8(9):ofab453. PMC: 8465328. DOI: 10.1093/ofid/ofab453. View

19.

Collard D, Nurmohamed N, Kaiser Y, Reeskamp L, Dormans T, Moeniralam H . Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: a prospective cohort study. BMJ Open. 2021; 11(2):e045482. PMC: 7902321. DOI: 10.1136/bmjopen-2020-045482. View

20.

Halaji M, Pournajaf A, Sadeghi F, Hasanzadeh A, Chehrazi M, Gholinia H . One-year prevalence and the association between SARS-CoV-2 cycle threshold, comorbidity and outcomes in population of Babol, North of Iran (2020-2021). Caspian J Intern Med. 2022; 13(Suppl 3):244-253. PMC: 9272954. DOI: 10.22088/cjim.13.0.244. View